Jan 14 (Reuters) – British cell and gene therapy manufacturer Oxford Biomedica confirmed on Wednesday that it has received an unsolicited cash offer from funds managed by EQT for all of its shares.
(Reporting by Unnamalai L in Bengaluru; Editing by Alan Barona)
